Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Food Chem Toxicol ; 47(6): 1085-92, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19425183

ABSTRACT

In this manuscript, the toxicology and safety of pomegranate seed oil (PSO) was evaluated by in vitro (Ames, chromosomal aberration), and in vivo toxicity tests (acute toxicity and 28-day toxicity in Wistar rats). No mutagenicity of PSO was observed in the absence and presence of metabolic activation up to precipitating concentrations of 5000 microg/plate (Ames test) or 333 microg/ml (chromosome aberration test). The acute oral toxicity study revealed no significant findings at 2000 mg PSO/kg body weight. In the 28-day dietary toxicity study PSO was dosed at concentrations of 0, 10,000, 50,000 and 150,000 ppm, which resulted in a mean intake of 0-0, 825-847, 4269-4330 and 13,710-14,214 mg PSO/kg body weight per day in males-females, respectively. At 150,000 ppm dietary exposure to PSO, a much higher dose than the level of PSO that elicits antidiabetic and anti-inflammatory efficacy, increased hepatic enzyme activities determined in plasma (aspartate, alanine aminotransferase and alkaline phosphatase) and increased liver-to-body weight ratios were observed. However, these effects might be the result of a physiological response to exposure to a very high level of a fatty acid which is not part of the normal diet, and are most likely not toxicologically relevant. The no observable adverse effect level (NOAEL) was 50,000 ppm PSO (=4.3 g PSO/kg body weight/day).


Subject(s)
Lythraceae/toxicity , Plant Oils/toxicity , Animals , Blood Cell Count , Cells, Cultured , Chromosome Aberrations/drug effects , Diet , Escherichia coli/genetics , Female , Humans , Liver Function Tests , Lymphocytes/drug effects , Male , Mutagenicity Tests , Mutagens/toxicity , Organ Size/drug effects , Rats , Rats, Wistar , Salmonella typhimurium/genetics , Seeds/toxicity , Sex Characteristics , Subcellular Fractions/drug effects
2.
Biochem Biophys Res Commun ; 253(2): 415-22, 1998 Dec 18.
Article in English | MEDLINE | ID: mdl-9878551

ABSTRACT

NADH:ubiquinone oxidoreductase (complex I) is an extremely complicated multiprotein complex located in the inner mitochondrial membrane. Its main function is the transport of electrons from NADH to ubiquinone, which is accompanied by translocation of protons from the mitochondrial matrix to the intermembrane space. Human complex I appears to consist of 41 subunits of which 34 are encoded by nDNA. Here we report the cDNA sequences of the hitherto uncharacterized 8 nuclear encoded subunits, all located within the hydrophobic protein (HP) fraction of complex I. Now all currently known 41 proteins of human NADH:ubiquinone oxidoreductase have been characterized and reported in literature, which enables more complete mutational analysis studies of isolated complex I-deficient patients.


Subject(s)
Cell Nucleus/enzymology , Cell Nucleus/genetics , DNA, Complementary/isolation & purification , NAD(P)H Dehydrogenase (Quinone)/chemistry , NAD(P)H Dehydrogenase (Quinone)/genetics , Adult , Aged , Amino Acid Sequence , Animals , Base Sequence , Cattle , Escherichia coli/enzymology , Escherichia coli/genetics , Evolution, Molecular , Female , Humans , Male , Middle Aged , Mitochondria/enzymology , Mitochondria/genetics , Molecular Sequence Data , NAD(P)H Dehydrogenase (Quinone)/isolation & purification , Neurospora crassa/enzymology , Neurospora crassa/genetics
SELECTION OF CITATIONS
SEARCH DETAIL